News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
FlexiTubes will showcase range of eco-friendly and innovative tube options
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Experts urge early detection & better access to care
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
